NCT04818216

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.

Detailed description

The study team chose a treatment protocol with NR as a treatment for patients who will be admitted with COVID-19 related illness and develop AKI after admission. Treatment duration will be for 10 days and the primary study endpoint will be the change in whole blood NAD+ from baseline to end of treatment in NR group vs placebo group. The study team will evaluate whole blood NAD+ levels as a marker of efficacy and biological effect of NR.

Conditions

• SARS-CoV-2 Infection
• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Placebo	Placebo capsule containing inert ingredient
DRUG	Nicotinamide riboside	250 mg Nicotinamide riboside capsules

Timeline

• Start date: 2021-06-11
• Primary completion: 2021-12-09
• Completion: 2022-01-03
• First posted: 2021-03-26
• Last updated: 2023-12-26
• Results posted: 2023-12-26

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study